Background and Purpose—The objective of the study is to compare the cost-effectiveness of
oral anticoagulants among atrial fibrillation patients at an increased stroke risk. Methods—A …

Background The perceived risk of serious bleeding is an obstacle to the use of oral
anticoagulation in East Asia. The efficacy and safety of apixaban in East Asian patients with …

Purpose: To systematically review available evidence of indirect comparisons from RCTs
and direct comparisons from observational studies regarding the comparative effectiveness …

Background AVERROES, a randomized controlled trial in high-risk patients with atrial
fibrillation, unsuitable for vitamin K antagonist therapy, demonstrated efficacy and safety of …

Background Atrial fibrillation is a major risk factor for stroke, which causes thousands of
deaths and sequelae. It is recommended that atrial fibrillation patients at medium or high risk …

2164 Circulation June 4, 2013 of predicted cTTR, 8 the benefit of apixaban was greatest at
centers with the lowest predicted TTR. However, the rate of major bleeding appeared to be …

Background The ARISTOTLE study investigated apixaban, at a dose of 5 mg PO bid, for the
prevention of stroke in patients with atrial fibrillation; however, it has been noted anecdotally …

Aims: This study compared the risk for major bleeding (MB) and healthcare economic
outcomes of patients with non-valvular atrial fibrillation (NVAF) after initiating treatment with …

Atrial fibrillation is a common, costly and morbid cardiovascular arrhythmia. Stroke
prevention remains the mainstay of treatment for atrial fibrillation, and the recent advent of …